13 months ago

2018 Annual Report


KEEPING WATCH ON OUR CELLULAR CLOCK RESEARCH In many ways, our futures are written in the history of our cells. But before this information can be deciphered, it must be measured, something that was difficult until recently. Now, thanks to a team led by investigators at Van Andel Research Institute (VARI) and Cedars-Sinai, scientists have a straightforward, computational way to measure cellular age, a feat that may lead to better, simpler screening and monitoring methods for cancer and other diseases. The findings, published in April, reveal a progressive, measurable loss of special chemical tags that regulate our genes and are detectable at the earliest stages of development. These changes continue throughout a person’s life, correlating with cellular rather than chronological age and foreshadowing alterations found in cancer cells. The work is the result of a long-time collaboration between senior authors Dr. Peter W. Laird and Dr. Hui Shen of VARI and Dr. Benjamin Berman then at Cedars-Sinai in Los Angeles. It builds on a 2011 discovery by Berman and Laird that first determined loss of these DNA marks — called methyl groups — occurs in specific areas of the genome in cancer. However, the techniques used back then were not able to detect this process occurring in normal cells. “Our cellular clock starts ticking the moment our cells begin dividing,” Laird said. “This method allows us to track the history of these past divisions and measure age-related changes to the genetic code that may contribute to both normal aging and dysfunction.” Each of the nearly 40 trillion cells in the human body can trace its lineage back to a single, fertilized egg cell containing the original copy of an individual’s DNA. Throughout a person’s lifetime, these cells divide, replacing old or damaged cells at different rates based on factors such as their function in the body, environmental insults and wound healing. Despite undergoing elaborate biological quality control checks, each cell division chips away at the genome’s integrity, leaving behind an accumulating number of changes. Chief among these is a dramatic shift in the number and location of methyl groups on the genome, part of a process that begins during fetal development and continues throughout a lifetime. “What is striking about the results from our new method is that they push back the start of this process to the earliest stages of in utero development,” Berman said. “That was completely surprising, given the current assumption that the process begins relatively late on the path to cancer. This finding also suggests that it may play a functional role relatively early in the formation of tumors.” While loss of DNA methyl groups, known as hypomethylation, is a common feature of many cancers, the mechanisms behind this phenomenon have until now been largely unknown. It is more profound in cancers that arise in tissues with a high turnover rate, such as the skin and the epithelium, the thin layer of cells that line many organs. It also features prominently in pediatric cancers such as medulloblastoma, a rare brain tumor. “Tissues with higher turnover rates are typically more susceptible to cancer development simply because there are more opportunities for errors to accumulate and force the change from a normal cell to a malignant one,” Shen said. “What we’re seeing is a normal process — cellular aging — augmented and accelerated once a cell becomes cancerous. The cumulative effect is akin to a runaway freight train.” Analysis and data interpretation for the project were led by Dr. Wanding Zhou, a postdoctoral fellow in the labs of Laird, Shen and VARI Chief Scientific Officer Dr. Peter A. Jones, along with co-first author Dr. Huy Q. Dinh, at the time a project scientist in Berman’s lab at the Cedars-Sinai Center for Bioinformatics and Functional Genomics. The study encompassed 39 diverse tumors and more than 340 human and 200 mouse datasets — the most in-depth study of its kind — and would not have been possible without massive swaths of publicly accessible data from large-scale sequencing projects, including The Cancer Genome Atlas. “This research project is a great example of combining our own data with externally available datasets to discover something new,” Zhou said. “If the project had been completed three years ago, the storyline would have been slightly different. Now, thanks to access to broader data, we can see that our method reveals a more general principle that extends all the way back to early development.” In addition to Zhou, Dinh, Shen, Laird and Berman, authors include Zachary Ramjan of VARI; and Dr. Daniel J. Weisenberger and Dr. Charles M. Nicolet, of University of Southern California Norris Comprehensive Cancer Center. 8 | VAN ANDEL INSTITUTE ANNUAL REPORT 2018 VAN ANDEL INSTITUTE ANNUAL REPORT 2018 | 9

Publications by Year